Rallybio to Present at Upcoming Investor Conferences in November

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:

• Stifel 2023 Healthcare Conference in New York, NY on Wednesday, November 15, 2023. Steve Uden, M.D., Chief Executive Officer will present a corporate overview at 3:00 p.m. EST.
• 6th Annual Evercore ISI HealthCONx Conference in Miami, FL on Tuesday, November 28, 2023. Steve Uden. M.D., Chief Executive Officer will participate in a fireside chat at 7:30 a.m. EST.

Live webcasts of both presentations will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each presentation.

About Rallybio

Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.

Rallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231028440323/en/